Retour sur lavenir.net
   ELIA GROUP 140.000 € (+1,67 %)     D'IETEREN GROUP 180.400 € (+0,56 %)     NYXOAH 1.700 € (+11,26 %)     AB INBEV 72.440 € (+1,86 %)     QRF(SUB)C15 0.035 € (+18,24 %)     ARGENX SE 830.800 € (+0,68 %)     AZELIS GROUP 9.885 € (+2,17 %)     COLRUYT 36.300 € (-0,82 %)     WDP 22.300 € (-0,54 %)     TITAN S.A. 52.000 € (+0,68 %)     SYENSQO 66.300 € (+1,22 %)     JENSEN-GROUP 84.800 € (+0,24 %)     AEDIFICA 69.700 € (+0,07 %)     ECONOCOM GROUP 1.485 € (-1,00 %)     EXMAR 11.000 € (-0,90 %)     NEXTENSA 46.320 € (+0,17 %)     INCLUSIO SA/NV 16.700 € (0,00 %)     VASTNED 29.500 € (-0,17 %)     ASCENCIO 51.900 € (-0,38 %)     CAMPINE 218.000 € (+0,46 %)     PROXIMUS 5.900 € (+0,43 %)     VIOHALCO 19.100 € (+1,06 %)     DEME GROUP 177.400 € (+2,19 %)     TUBIZE-FIN 224.400 € (-1,41 %)     WERELDHAVE BELGIUM 52.800 € (+0,38 %)     GIMV 45.950 € (+0,33 %)     CARE PROPERTY INV. 12.600 € (-1,25 %)     BREDERODE 104.600 € (+0,38 %)     SHURGARD 26.400 € (-0,38 %)     SOFINA 230.600 € (+0,61 %)     LOTUS BAKERIES 11 780.000 € (+1,38 %)     MELEXIS 78.550 € (+1,03 %)     UMICORE 21.360 € (+2,40 %)     TINC 11.260 € (-0,71 %)     CENERGY 23.000 € (+3,88 %)     EVS 27.500 € (+0,36 %)     HYLORIS 4.520 € (+0,89 %)     HOME INVEST BE. 19.200 € (-0,31 %)     BEKAERT 40.650 € (+2,52 %)     FLUXYS BELGIUM D 19.450 € (-1,52 %)     VAN DE VELDE 30.000 € (-0,33 %)     CMB.TECH 13.220 € (+2,48 %)     ONWARD MEDICAL 2.620 € (+0,77 %)     KINEPOLIS GROUP 37.000 € (+1,37 %)     CIE BOIS SAUVAGE 307.000 € (-0,65 %)     BARCO 8.520 € (+1,97 %)     WHAT'S COOKING GP 145.500 € (+3,56 %)     IBA 17.700 € (-0,11 %)     FAGRON 24.600 € (+0,82 %)     MONTEA 67.500 € (-0,59 %)     KBC 120.650 € (-0,86 %)     AGFA-GEVAERT 0.420 € (-0,24 %)     VGP 87.400 € (+0,34 %)     AGEAS 70.700 € (+0,43 %)     BPOST 1.670 € (+5,16 %)     SOLVAY 26.360 € (-0,60 %)     BANQUP GROUP 2.100 € (+0,96 %)     DECEUNINCK 2.275 € (+1,34 %)     TESSENDERLO 20.350 € (+0,25 %)     UCB 259.500 € (-1,93 %)  
   SANOFI 75.810 € (+0,74 %)     GETLINK SE 18.730 € (+1,19 %)     AKZO NOBEL 60.800 € (+1,00 %)     ASR NEDERLAND 66.560 € (-0,03 %)     CAPGEMINI 91.900 € (+0,37 %)     SHELL PLC 33.885 € (-0,24 %)     GENFIT 12.940 € (+22,31 %)     ASM INTERNATIONAL 975.600 € (+4,10 %)     TECHNIP ENERGIES 34.520 € (+3,42 %)     AIR LIQUIDE 180.300 € (+0,16 %)     AHOLD DEL 35.920 € (-0,66 %)     AB SCIENCE 0.773 € (+0,78 %)     ING GROEP N.V. 28.290 € (+0,21 %)     ALLFUNDS GROUP 8.575 € (+0,53 %)     MICHELIN 34.840 € (+0,35 %)     CROSSJECT 1.800 € (+0,67 %)     SBM OFFSHORE 30.680 € (+2,40 %)     DSM FIRMENICH AG 85.000 € (+2,29 %)     ACCOR 50.900 € (+0,35 %)     VOLTALIA 7.200 € (+1,27 %)     AIR FRANCE -KLM 13.395 € (-0,37 %)     VALEO 13.275 € (+2,55 %)     EUROPACORP 0.266 € (+9,92 %)     PHILIPS KON 24.690 € (+1,94 %)     ENGIE 27.730 € (+2,06 %)     LEGRAND 143.350 € (+1,59 %)     DNXCORP 17.750 € (-0,56 %)     UMG 18.995 € (-0,73 %)     ICADE 19.230 € (-0,83 %)     JCDECAUX 20.100 € (+1,11 %)     IPSEN 170.700 € (-0,23 %)     EUROCOMMERCIAL 27.450 € (0,00 %)     GECINA 72.800 € (-0,21 %)     UNILEVER 54.080 € (-0,39 %)     ADYEN 862.300 € (+0,85 %)     TKH GROUP 43.820 € (+2,19 %)     ABC ARBITRAGE 5.260 € (+0,57 %)     L'OREAL 382.450 € (-1,42 %)     STELLANTIS NV 4.930 € (-3,47 %)     AMG 33.080 € (+2,61 %)     SPIE 52.750 € (+5,50 %)     HERMES INTL 1 641.000 € (-0,36 %)     FUGRO 9.475 € (+0,74 %)     EXAIL TECHNOLOGIES 122.500 € (+0,99 %)     ARCADIS 33.780 € (+2,80 %)     S.E.B. 48.780 € (+0,58 %)     DASSAULT SYSTEMES 18.495 € (-0,94 %)     ORANGE 15.860 € (-0,06 %)     RENAULT 26.370 € (+1,66 %)     WOLTERS KLUWER 57.620 € (+0,07 %)     AIRBUS 206.150 € (+1,10 %)     FRANCAISE ENERGIE 42.100 € (+5,25 %)     VALNEVA 2.337 € (+4,10 %)     APERAM 45.500 € (+3,60 %)     THALES 238.200 € (-0,92 %)     ARCELORMITTAL SA 58.600 € (+5,89 %)     AEGON 7.672 € (+0,87 %)     NN GROUP 75.940 € (-0,24 %)     DRONE VOLT 0.389 € (+2,42 %)     BOLLORE 4.144 € (+0,83 %)  
News Réglementées
28/03/2023 07:00

Evolva goes Responsible Care at in-cosmetics 2023

Evolva Holding SA / Key word(s): Product Launch
Evolva goes Responsible Care at in-cosmetics 2023

28.03.2023 / 07:00 CET/CEST


PRESS RELEASE

  • Evolva is globally launching an exclusive line of nature-based high-purity ingredients and bio-functionals for the personal care industry, produced in a sustainable manner 
  • New science backed up by proprietary research studies by Evolva unlock an innovative spectrum of cosmetic claims for topical skin and scalp applications
  • This enables customers to create differentiated consumer experiences with proven effects for skin and hair beautification in an environmentally responsible way

 

Reinach, 28 March 2023 — Evolva (SIX: EVE), a pioneer in the field of natural molecules and industrial biotech, will launch its “Responsible Care” program for the personal care industry at the trade fair in-cosmetics in Barcelona, Spain, on 28-30 March 2023. As announced in connection with the company’s mid-term plan, personal care represents a new industry segment which Evolva intends to address with proven molecules from its Health Ingredients’ product portfolio, Resveratrol and L-Arabinose. Designed and produced via its unique precision-fermentation platform, these active ingredients are available at scale at the highest quality and purity levels and without drawing from the planet’s natural resources.

 

Research backed-evidence

Recent extensive research by Evolva unlocked an innovative spectrum of science-backed claims. Accessing the formulator for cosmetic consumer products to new levels of customization for skin and hair beautification is supported by Evolva’s proprietary scientific studies. Specifically, Evolva at in-cosmetics will be featuring an exclusive line of two responsible ingredients and their powerful science: JUNEO and LARALLY.

 

JUNEO - The Beauty Powerhouse is the nature-based responsible Resveratrol of highest purity with many multi-funtional benefits also on skin and hair as evidenced by new scientific studies. With proven benefits such as detoxifying, protecting, rejuvenating and repairing damaged cells, new application fields in the areas of oxidative stress, skin aging and hair protection are being addressed in an environmentally responsible way.

 

LARALLY – The Skin Microbiome Influencer is a high-purity natural responsible bioactive
L-Arabinose. It can play a key role in influencing and safeguarding the balance of the skin’s microbiota. Recent extensive research by Evolva confirms topical LARALLY works for the very first time as a bioactive for the microbiome ecosystem on the human skin, qualifying Larally™ as powerful skin microbiome influencer (patent pending).

 

Both products enable personal care manufacturers looking for novel and sustainable solutions to design innovative consumer products delivering benefits perfectly in line with today’s mindful consumer expectations: Modern, nature-based solutions combining responsible ingredients, with proven benefits and claims backed by science.

 

At the Evolva stand (AH94), customers can get in touch with the Evolva experts to learn about the exclusive line of responsible ingredients and their powerful science enabling to unlock customagic consumer experiences. Evolva has created a number of responsible product concepts for the event and will promote them under the headline: Think customagic!

 

Anne De Vos, Chief Commercial Officer of Evolva, comments:” We are very excited about the launch of our line of responsible active ingredients for the personal care industry. JUNEO as Evolva’s responsible Resveratrol and LARALLY as Evolva’s responsible L-Arabinose are perfectly in line with today’s mindful consumer’s expectations for nature-based and sustainable ingredients with proven benefits and claims, enabling our customers to unlock desired consumer experiences.”

 

Alessandra Batelli, Senior Director Business Development, adds: “We are very much looking forward to sharing the news about our responsible ingredients at the in-cosmetics with the industry’s key players. With a new spectrum of innovative personal care claims, we enable our customers to realize great consumer concepts: Think customagic.”

 

Christian Wichert, CEO of Evolva, adds: “The entire team is excited about introducing Evolva’s Responsible Care concept to the personal care industry, thereby addressing a new and interesting market segment for us. Starting with in-cosmetics 2023 we are building momentum to successfully introduce our exclusive line of ingredients backed by science to our customers. We are fully focused on capturing these attractive market opportunities and on bringing Evolva to the next level”.

 

 

 

Important dates

18 April 2023  Annual General Meeting

24 Auguts 2023 Half-year 2023 results 

 

 

Contact

Doris Rudischhauser

Head of Investor Relations and Corporate Communications

+41 79 410 81 88

dorisr@evolva.com

 

 

 

About Evolva

Evolva is a Swiss biotech company focused on the research, development and commercialization of ingredients based on nature. We have leading businesses in Flavors and Fragrances, Health Ingredients and Health Protection. Evolva’s employees, half of which are women, are dedicated to make the best products that can contribute to health, wellness and sustainability. Find out more at evolva.com and connect with us on LinkedIn.

For Evolva multimedia content, please visit: evolva.com/multimedia-library.

 

Disclaimer
This announcement is not an offer of securities into the United States. The securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”), and may not be offered, pledged, sold, delivered or otherwise transferred, directly or indirectly, in the United States, except pursuant to an exemption from, or transaction not subject to, the registration requirements of the Securities Act. No public offering of securities is being made in the United States. Further, the securities referred to herein have not been and will not be registered under the applicable securities laws of Canada, Australia or Japan or under the applicable securities laws of any other jurisdiction where to do so might constitute a violation of such laws.             
This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.

 



End of Media Release


Language:English
Company:Evolva Holding SA
Duggingerstrasse 23
4153 Reinach
Switzerland
Phone:+41 61 485 20 00
Internet:www.evolva.com
ISIN:CH0021218067
Valor:2121806
Listed:SIX Swiss Exchange
EQS News ID:1593737

 
End of NewsEQS News Service

1593737  28.03.2023 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1593737&application_name=news&site_id=symex

Source : Webdisclosure.com

© 2026 Tous droits réservés
Cotations différées d'au moins 15 minutes (Paris, Amsterdam, Bruxelles, Lisbonne).
Cotations à la clôture (Francfort, New-York, Londres, Zurich).
Flux de cotations : Euronext (Places Euronext et Cours des Devises).
Bourse : technologie Cote Boursière